Arcus Historical Cash Flow

RCUS Stock

USD 8.49 0.23 2.78%

Analysis of Arcus Biosciences cash flow over time is an excellent tool to project Arcus Biosciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 122.6 M or Other Cashflows From Financing Activities of 1.9 M as it is a great indicator of Arcus Biosciences ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Arcus Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arcus Biosciences is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.

About Arcus Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Arcus balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Arcus's non-liquid assets can be easily converted into cash.

Arcus Biosciences Cash Flow Chart

At this time, Arcus Biosciences' Change In Cash is comparatively stable compared to the past year. Stock Based Compensation is likely to gain to about 79.8 M in 2025, despite the fact that Free Cash Flow is likely to grow to (167.2 M).

Stock Based Compensation Begin Period Cash Flow Capital Expenditures Change To Operating Activities

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Arcus Biosciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Arcus Biosciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most accounts from Arcus Biosciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Arcus Biosciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.At this time, Arcus Biosciences' Change In Cash is comparatively stable compared to the past year. Stock Based Compensation is likely to gain to about 79.8 M in 2025, despite the fact that Free Cash Flow is likely to grow to (167.2 M).

Arcus Biosciences cash flow statement Correlations

	Sale Purchase Of Stock	Investments	Change In Cash	Stock Based Compensation	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Change To Operating Activities	Net Income	End Period Cash Flow	Change To Netincome	Change To Liabilities	Change To Account Receivables	Change Receivables	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Issuance Of Capital Stock	Change To Inventory	Dividends Paid
Sale Purchase Of Stock		0.16	-0.06	-0.78	0.13	-0.13	-0.61	-0.66	-0.24	-0.5	-0.79	0.61	-0.7	-0.77	0.59	-0.3	-0.94	-0.34	0.59	-0.13	0.28	0.38
Investments	0.16		-0.84	-0.09	-0.78	-0.72	0.11	-0.07	-0.67	0.24	-0.33	0.14	-0.59	-0.12	0.01	-0.58	-0.2	-0.6	-0.13	-0.5	0.56	0.03
Change In Cash	-0.06	-0.84		-0.15	0.69	0.58	-0.47	-0.16	0.52	-0.51	0.12	0.02	0.32	-0.12	0.21	0.28	0.01	0.62	0.41	0.59	-0.25	-0.08
Stock Based Compensation	-0.78	-0.09	-0.15		-0.25	0.12	0.87	0.88	0.34	0.68	0.94	-0.82	0.8	1.0	-0.87	0.37	0.86	0.02	-0.89	0.02	-0.36	-0.61
Free Cash Flow	0.13	-0.78	0.69	-0.25		0.88	-0.35	-0.24	0.54	-0.46	-0.1	0.0	0.2	-0.21	0.07	0.73	-0.17	0.23	0.29	-0.03	-0.73	0.28
Change In Working Capital	-0.13	-0.72	0.58	0.12	0.88		-0.05	0.17	0.5	-0.3	0.27	-0.46	0.43	0.16	-0.35	0.83	0.14	0.25	0.01	-0.11	-0.81	0.02
Begin Period Cash Flow	-0.61	0.11	-0.47	0.87	-0.35	-0.05		0.8	0.09	0.88	0.75	-0.63	0.68	0.85	-0.74	0.33	0.73	-0.11	-0.89	-0.15	-0.33	-0.26
Depreciation	-0.66	-0.07	-0.16	0.88	-0.24	0.17	0.8		0.17	0.47	0.87	-0.87	0.72	0.88	-0.81	0.29	0.8	0.1	-0.72	0.06	-0.27	-0.46
Other Non Cash Items	-0.24	-0.67	0.52	0.34	0.54	0.5	0.09	0.17		-0.05	0.34	-0.18	0.52	0.38	-0.29	0.66	0.27	-0.06	-0.35	0.08	-0.65	-0.38
Capital Expenditures	-0.5	0.24	-0.51	0.68	-0.46	-0.3	0.88	0.47	-0.05		0.53	-0.29	0.52	0.64	-0.47	0.16	0.53	-0.14	-0.79	-0.09	-0.17	-0.07
Change To Operating Activities	-0.79	-0.33	0.12	0.94	-0.1	0.27	0.75	0.87	0.34	0.53		-0.84	0.89	0.94	-0.79	0.37	0.87	0.31	-0.71	0.26	-0.35	-0.6
Net Income	0.61	0.14	0.02	-0.82	0.0	-0.46	-0.63	-0.87	-0.18	-0.29	-0.84		-0.65	-0.84	0.91	-0.44	-0.7	-0.09	0.62	0.12	0.42	0.56
End Period Cash Flow	-0.7	-0.59	0.32	0.8	0.2	0.43	0.68	0.72	0.52	0.52	0.89	-0.65		0.8	-0.6	0.6	0.78	0.41	-0.61	0.33	-0.58	-0.29
Change To Netincome	-0.77	-0.12	-0.12	1.0	-0.21	0.16	0.85	0.88	0.38	0.64	0.94	-0.84	0.8		-0.89	0.4	0.85	0.0	-0.89	0.0	-0.39	-0.64
Change To Liabilities	0.59	0.01	0.21	-0.87	0.07	-0.35	-0.74	-0.81	-0.29	-0.47	-0.79	0.91	-0.6	-0.89		-0.52	-0.64	0.22	0.84	0.31	0.51	0.55
Change To Account Receivables	-0.3	-0.58	0.28	0.37	0.73	0.83	0.33	0.29	0.66	0.16	0.37	-0.44	0.6	0.4	-0.52		0.3	-0.05	-0.42	-0.31	-1.0	0.04
Change Receivables	-0.94	-0.2	0.01	0.86	-0.17	0.14	0.73	0.8	0.27	0.53	0.87	-0.7	0.78	0.85	-0.64	0.3		0.34	-0.64	0.14	-0.28	-0.46
Cash And Cash Equivalents Changes	-0.34	-0.6	0.62	0.02	0.23	0.25	-0.11	0.1	-0.06	-0.14	0.31	-0.09	0.41	0.0	0.22	-0.05	0.34		0.38	0.76	0.08	0.09
Cash Flows Other Operating	0.59	-0.13	0.41	-0.89	0.29	0.01	-0.89	-0.72	-0.35	-0.79	-0.71	0.62	-0.61	-0.89	0.84	-0.42	-0.64	0.38		0.29	0.42	0.45
Issuance Of Capital Stock	-0.13	-0.5	0.59	0.02	-0.03	-0.11	-0.15	0.06	0.08	-0.09	0.26	0.12	0.33	0.0	0.31	-0.31	0.14	0.76	0.29		0.34	-0.08
Change To Inventory	0.28	0.56	-0.25	-0.36	-0.73	-0.81	-0.33	-0.27	-0.65	-0.17	-0.35	0.42	-0.58	-0.39	0.51	-1.0	-0.28	0.08	0.42	0.34		-0.06
Dividends Paid	0.38	0.03	-0.08	-0.61	0.28	0.02	-0.26	-0.46	-0.38	-0.07	-0.6	0.56	-0.29	-0.64	0.55	0.04	-0.46	0.09	0.45	-0.08	-0.06

Click cells to compare fundamentals

Arcus Biosciences Account Relationship Matchups

Arcus Biosciences cash flow statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Investments	(431.3M)	(28.8M)	(413M)	213M	(84M)	(88.2M)
Change In Cash	115.5M	(22.7M)	58M	(79M)	23M	24.2M
Stock Based Compensation	22M	55M	65M	73M	76M	79.8M
Free Cash Flow	108.1M	(282.2M)	426M	(330M)	(176M)	(167.2M)
Change In Working Capital	208.1M	(375.6M)	623M	(71M)	22M	20.9M
Begin Period Cash Flow	58.1M	173.6M	151M	209M	130M	122.6M
Total Cashflows From Investing Activities	59.2M	(434.4M)	(3.9M)	(413M)	(371.7M)	(353.1M)
Other Cashflows From Financing Activities	4.7M	12.3M	33M	8M	2M	1.9M
Depreciation	4.2M	3.8M	6M	8M	10M	5.3M
Other Non Cash Items	(46K)	3.5M	11M	(9M)	5M	5.3M
Capital Expenditures	3.1M	26.1M	12M	24M	6M	10.6M
Total Cash From Operating Activities	111.2M	(256.2M)	438M	(306M)	(170M)	(161.5M)
Change To Operating Activities	531K	21.3M	14.1M	23M	26.5M	27.8M
Net Income	(122.9M)	52.8M	(267M)	(307M)	(283M)	(268.9M)
Total Cash From Financing Activities	1.1M	438.7M	237.3M	33M	277M	162.2M
End Period Cash Flow	173.6M	150.9M	209M	130M	153M	135.6M
Other Cashflows From Investing Activities	61.1M	(431M)	22M	3M	2.7M	2.8M
Change To Netincome	10.2M	21.8M	54.5M	76M	87.4M	91.8M
Change To Liabilities	3.3M	24.1M	4.9M	(104M)	(93.6M)	(88.9M)
Change To Account Receivables	(917K)	(17.0M)	704M	15M	28M	26.6M
Issuance Of Capital Stock	433.8M	220.2M	23M	36M	228M	122.0M
Change To Inventory	21.3M	14.1M	(704M)	(15M)	(13.5M)	(14.2M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcus Stock Analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arcus Historical Cash Flow

About Arcus Cash Flow Analysis

Arcus Biosciences Cash Flow Chart

Stock Based Compensation

Begin Period Cash Flow

Capital Expenditures

Arcus Biosciences cash flow statement Correlations

Arcus Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arcus Biosciences cash flow statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Arcus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Change To Netincome	+ 1.0	Stock Based Compensation
Change To Operating Activities	+ 0.94	Stock Based Compensation
Change To Netincome	+ 0.94	Change To Operating Activities
Change To Liabilities	+ 0.91	Net Income
End Period Cash Flow	+ 0.89	Change To Operating Activities
Depreciation	+ 0.88	Stock Based Compensation

Change To Inventory	- 1.0	Change To Account Receivables
Change Receivables	- 0.94	Sale Purchase Of Stock
Cash Flows Other Operating	- 0.89	Change To Netincome
Change To Liabilities	- 0.89	Change To Netincome
Cash Flows Other Operating	- 0.89	Begin Period Cash Flow
Cash Flows Other Operating	- 0.89	Stock Based Compensation